



Anti-Narcotic Patches: A Novel Approach for Addiction Management

¹Mr. Ajay Bhanudas Suralkar, ²Miss. Ashwini Khairnar, ³Dr. D. K. Vir,

⁴Mr. Yash Kishor Pendharkar

¹Student, ²Associate professor (Guide), ³Principal, ⁴Student
B-pharmacy Final year

Shree Goraksha College of Pharmacy & Research Centre, Chhatrapati Sambhaji Nagar, India.

Date of Submission: 28-12-2024

Date of Acceptance: 08-01-2025

Abstract

Anti-narcotic patches, a form of transdermal drug delivery system, have emerged as an innovative and effective tool in managing substance addiction, including nicotine and opioid dependence. These patches provide sustained drug delivery to alleviate withdrawal symptoms and reduce cravings, enhancing compliance and minimizing relapse risks. This review explores the uses, mechanisms of action (MOA), advantages, challenges, and future prospects of anti-narcotic patches in addiction therapy.

Keywords: Nicotine Replacement Therapy (NRT), Opioid Addiction Management, Sustained Drug Release


I. Introduction

Substance addiction, a pervasive issue affecting individuals and communities worldwide, remains a major public health challenge. It encompasses the misuse of substances such as tobacco, opioids, and other narcotics, leading to severe health implications, societal disruption, and significant economic burdens. The complexity of addiction is further compounded by its multidimensional impact on physical, psychological, and social well-being, necessitating comprehensive and effective treatment strategies. Conventional

approaches to addiction treatment, including oral medications, counseling programs, and injectable therapies, have been the cornerstone of rehabilitation efforts. Despite their effectiveness in certain cases, these methods are often associated with notable drawbacks. Oral medications frequently encounter issues of patient non-compliance due to forgetfulness, stigma, or adverse side effects. Counseling, while essential for behavioral modifications, requires sustained engagement and access to skilled professionals, which can be a challenge in resource-limited settings. Injectable therapies, on the other hand, pose risks such as incorrect dosing, pain at the injection site, and potential complications arising from invasive administration.

In light of these limitations, innovative solutions are imperative to enhance the efficacy and accessibility of addiction treatment. Anti-narcotic patches have emerged as a promising alternative, offering a non-invasive and efficient means of drug delivery. These transdermal patches ensure a controlled and sustained release of therapeutic agents, enabling consistent drug levels in the bloodstream. By mitigating the risks of overdose, enhancing compliance, and simplifying administration, anti-narcotic patches present a novel approach that aligns with patient-centric care and improves overall treatment outcomes.

Geopolymer-integrated fentanyl patch



Tamper-resistant tests simulating:

Solvent extraction



Chewing



Smoking



Indigestion





This paradigm shift toward transdermal delivery not only addresses the existing gaps in addiction management but also underscores the potential of

advanced drug delivery systems in combating substance dependence effectively.

1. Mechanism of Action (MOA) :





Figure 1 The MOA of anti-narcotic patches and Pain treatment.

The MOA of anti-narcotic patches varies depending on the drug used. Below are the MOAs for common patches:

1. **Nicotine Patches (Smoking Cessation):**
 - Provide controlled levels of nicotine to the bloodstream, reducing withdrawal symptoms and cravings.
 - Nicotine binds to **nicotinic acetylcholine receptors (nAChRs)**, stimulating dopamine release and gradually tapering dependence.
2. **Buprenorphine Patches (Opioid Dependence):**
 - Buprenorphine acts as a **partial agonist** at the **mu-opioid receptor**, offering relief from cravings and withdrawal symptoms without causing a significant high.
 - Its antagonistic properties prevent misuse of other opioids.



3. **Combination Patches (Buprenorphine-Naloxone):**
 - While buprenorphine alleviates withdrawal, **naloxone**, an opioid antagonist, blocks opioid effects, reducing misuse potential.
4. **Clonidine Patches:**
 - Reduces withdrawal symptoms by modulating sympathetic nervous system activity through its action on **alpha-2 adrenergic receptors**.



II. Formulation :

The basic components of a TDDS include polymer matrix, membrane, drug, penetration enhancers, pressure-sensitive adhesives (PSA), backing

laminates, and release coating, the characteristics, we can observe the composition of each layer that compose different types of TDDS.




Figure 2 Anti-Narcotic Patches Formulation.

Starting from left to right we have single-layer drug-in-adhesive and multi-layer drug-in-adhesive, which are similar in that they contain the drug in the adhesive layer and a solid-state, except for the multilayer, which has a membrane. Finally, we have the microneedle patches, which have penetration to the dermis, with biodegradable needles, from which the solid drug will be released. All these TDDS are intended for the active ingredient to travel to the capillaries between the dermis and the hypodermis.

2. Uses and Applications :

1. Nicotine Replacement Therapy (NRT):

- ✓ Helps smokers gradually quit by delivering decreasing doses of nicotine.
- ✓ Reduces withdrawal symptoms such as irritability, anxiety, and cravings.

2. Opioid Addiction Management:

- ✓ Buprenorphine patches provide a safer alternative to oral or injectable treatments, reducing the risk of overdose.

3. Relapse Prevention:

- ✓ Sustained drug delivery stabilizes brain chemistry, reducing the likelihood of relapse in recovering addicts.

4. Withdrawal Symptom Management:

- ✓ Alleviates physical and psychological symptoms associated with substance withdrawal, ensuring a smoother recovery process.

5. Advantages of Anti-Narcotic Patches :

- ✓ **Non-Invasive:** Easy to apply and avoids the discomfort of injections.
- ✓ **Sustained Drug Release:** Provides a steady therapeutic dose, minimizing peaks and troughs.
- ✓ **Improved Compliance:** Convenient and discreet, enhancing patient adherence to treatment.
- ✓ **Reduced Risk of Overdose:** Controlled release minimizes the potential for misuse.
- ✓ **Minimal Side Effects:** Bypasses the gastrointestinal tract, reducing systemic side effects.

6. Challenges and Limitations :

- ✓ **Skin Irritation:** Prolonged use may cause local skin reactions such as redness or itching.
- ✓ **Cost:** Anti-narcotic patches can be expensive compared to traditional treatments.



- ✓ **Limited Drug Options:** Not all addiction management drugs are suitable for transdermal delivery.
- ✓ **Adherence Issues:** Improper application or premature removal of patches can reduce efficacy.

7. Future Prospects:

Advancements in transdermal drug delivery, such as micro-needle patches and enhanced permeation techniques, could significantly enhance the effectiveness and versatility of anti-narcotic patches. Micro-needles enable the drug to penetrate the skin more efficiently, allowing for better absorption and quicker onset of action. Enhanced permeation technologies further improve drug diffusion through the skin, ensuring consistent therapeutic levels. Moreover, the integration of wearable technology for real-time monitoring and dose adjustment holds great promise for personalized addiction management. By tracking patient responses and adjusting drug delivery accordingly, wearable devices could provide a tailored, dynamic treatment approach, ensuring optimal outcomes and reducing the risk of overdose or underdose. These innovations pave the way for more effective, adaptable, and patient-centered solutions in addiction therapy.




Figure 3 Future Prospects in TDDS

III. Conclusion :

Anti-narcotic patches offer a promising advancement in addiction treatment by providing a non-invasive, sustained-release drug delivery system. These patches help manage substance dependence more effectively by ensuring consistent therapeutic levels, improving patient compliance,

and reducing the risks of relapse and overdose. Traditional treatments like oral medications and injectable therapies often face challenges such as non-compliance and inconsistent drug levels. Anti-narcotic patches address these issues by offering a more controlled and convenient alternative. While there are still limitations to be addressed, including long-term efficacy and cost, these patches present a valuable addition to addiction management strategies. Further research and development are necessary to optimize their effectiveness and broaden their clinical applications in combating substance addiction.

References:

- [1]. Prausnitz MR, Langer R. Transdermal drug delivery. *Nat Biotechnol* 2008;26:1261-8. 10.1038/nbt.1504.
- [2]. Pegoraro C, MacNeil S, Battaglia G. Transdermal drug delivery: from micro to nano. *Nanoscale* 2012;4:1881-94. 10.1039/c2nr11606e.
- [3]. Shwayder T, Akland T. Neonatal skin barrier: structure, function, and disorders. *Dermatol Ther* 2005;18:87-103. 10.1111/j.1529-8019.2005.05011.x.
- [4]. Fluhr JW, Darlenski R, Taieb A, et al. Functional skin adaptation in infancy—almost complete but not fully competent. *Exp Dermatol* 2010;19:483-92. 10.1111/j.1600-0625.2009.01023.x.
- [5]. Levin J, Maibach H. The correlation between transepidermal water loss and percutaneous absorption: an overview. *J Control Release* 2005;103:291-9. 10.1016/j.jconrel.2004.11.035.
- [6]. Chiou YB, Blume-Peytavi U. Stratum corneum maturation. A review of neonatal skin function. *Skin Pharmacol Physiol* 2004;17:57-66. 10.1159/000076015.
- [7]. Potts RO, Guy RH. Predicting skin permeability. *Pharm Res* 1992;9:663-9. 10.1023/A:1015810312465.
- [8]. Turner NG, Guy RH. Ionophoretic transport pathways: dependence on penetrant physicochemical properties. *J Pharm Sci* 1997;86:1385-9. 10.1021/js970046z.
- [9]. Delgado-Charro MB, Richard H. Effective use of transdermal drug delivery in children. *Advanced Drug Delivery Reviews* 2014;73:63-82. 10.1016/j.addr.2013.11.014.
- [10]. Ruggiero A, Barone G, Liotti L, et al. Safety and efficacy of fentanyl administered by patient controlled analgesia in children with cancer pain. *Support Care Cancer*



- 2007;15:569-73. 10.1007/s00520-006-0193-8.
- [11]. Paut O, Camboulives J, Viard L. Pharmacokinetics of transdermal fentanyl in the peri-operative period in young children. *Anaesthesia* 2000;55:1202-7. 10.1046/j.1365-2044.2000.01615-3.x.
- [12]. Twycross R, Prommer EE, Mihalyo M, et al. fentanyl (transmucosal). *J Pain Symptom Manage* 2012;44:131-49. 10.1016/j.jpainsymman.2012.05.001.
- [13]. Triarico S, Capozza MA, Mastrangelo S, et al. Intranasal therapy with opioids for children and adolescents with cancer: results from clinical studies. *Support Care Cancer* 2019;27:3639-45. 10.1007/s00520-019-04854-6.
- [14]. Geary T, Negus A, Anderson BJ, et al. Perioperative management of the child on long-term opioids. *Paediatr Anaesth* 2012;22:189-202. 10.1111/j.1460-9592.2011.03737.x.
- [15]. Finkel J C, Finley A, Greco C, et al. Transdermal fentanyl in the management of children with chronic severe pain. Results from an international study. *Cancer* 2005;104:2847-57. 10.1002/cncr.21497
- [16]. Lane ME. The transdermal delivery of fentanyl. *Eur J Pharm Biopharm* 2013;84:449-55. 10.1016/j.ejpb.2013.01.018
- [17]. Collins JJ, Dunkel IJ, Gupta SK, et al. Transdermal fentanyl in children with cancer pain: feasibility, tolerability, and pharmacokinetic correlates. *J Pediatr* 1999;134:319-23. 10.1016/S0022-3476(99)70457-9
- [18]. Zernikow B, Michel E, Anderson B. Transdermal fentanyl in childhood and adolescence: a comprehensive literature review. *J Pain* 2007;8:187-207. 10.1016/j.jpain.2006.11.008
- [19]. Ziesenitz VC, Vaughns JD, Koch G. Pharmacokinetics of fentanyl and Its Derivatives in Children: A Comprehensive Review. *Clin Pharmacokinet* 2018;57:125-49. 10.1007/s40262-017-0569-6
- [20]. Muijsers RBR, Wagstaff AJ. Transdermal fentanyl. An updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. *Drugs* 2001;61:2289-307. 10.2165/00003495-200161150-00014
- [21]. Virk MS, Arttamangkul S, Birdsong WT, et al. Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. *J Neurosci* 2009;29:7341-8. 10.1523/JNEUROSCI.3723-08.2009
- [22]. Butler S. Buprenorphine-clinically useful but often misunderstood. *Scand J Pain* 2013;4:148-52. 10.1016/j.sjpain.2013.05.004
- [23]. Davis MP, Pasternak G, Behm B. Treating chronic pain: an overview of clinical studies centered on the buprenorphine option. *Drugs* 2018;78:1211-28. 10.1007/s40265-018-0953-z
- [24]. McPherson J, Rivero G, Baptist M, et al. Mu-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. *Mol Pharmacol* 2010;78:756-66. 10.1124/mol.110.066613
- [25]. Zaki PA, Keith DE, Brine GA, et al. Ligand-induced changes in surface mu-opioid receptor number: relationship to G protein activation? *J Pharmacol Exp Ther* 2000;292:1127-34.
- [26]. Sadée W, Rosenbaum JS, Herz A. Buprenorphine: differential interaction with opiate receptor subtypes in vivo. *J Pharmacol Exp Ther* 1982;223:157-62.
- [27]. Khanna IK, Pillarisetti S. Buprenorphine – an attractive opioid with underutilized potential in treatment of chronic pain. *J Pain Res* 2015;8:859-70.
- [28]. Cote J, Montgomery L. Sublingual buprenorphine as an analgesic in chronic pain: a systematic review. *Pain Med* 2014;15:1171-8. 10.1111/pme.12386
- [29]. Yekkirala AS, Roberson DP, Bean BP, et al. Breaking barriers to novel analgesic drug development. *Nat Rev Drug Discov* 2017;16:810. 10.1038/nrd.2017.202
- [30]. Michel E, Anderson BJ, Zernikow B. Buprenorphine TTS for children—a review of the drug's clinical pharmacology. *Paediatr Anaesth* 2011;21:280-90. 10.1111/j.1460-9592.2010.03437.x.
- [31]. Attinà G, Ruggiero A, Maurizi P, et al. Transdermal buprenorphine in children with cancer-related pain. *Pediatr Blood Cancer* 2009;52:125-7. 10.1002/pbc.21736.
- [32]. Prapaitrakool S, Hollmann MW, Wartenberg HC. Use of buprenorphine in children with chronic pseudoobstruction syndrome case series and review of literature. *Clin J Pain*



2012;28:722-5.

10.1097/AJP.0b013e318243f609.

- [33]. Ruggiero A, Coccia P, Arena R, et al. Efficacy and safety of transdermal buprenorphine in the management of children with cancer-related pain. *Pediatr Blood Cancer* 2013;60:433-7. 10.1002/pbc.24332.